Missing A Tooth? Scientists Develop New Drug that Regrows Teeth
Scientists in Japan have announced that they are moving forward with a drug that is capable of regrowing human teeth, Popular Mechanics reports.
The drug works by suppressing an antibody called uterine sensitization–associated gene-1 (USAG-1). In ferrets and mice, this protein is shown to inhibit the growth of teeth, according to Dentistry Today.
In a press release, Dr. Katsu Takahashi, a lead author of a study from Kyoto University and the University of Fukui, said, "We knew that suppressing USAG-1 benefits tooth growth. What we did not know was whether it would be enough.'
He adds, "Ferrets are diphyodont animals with similar dental patterns to humans.'
An article from Dentistry Today reports that researchers found that the 'USAG-1 protein could limit the growth of teeth in mice.' And that suppressing the protein would 'potentially invite their teeth to grow.'
Trials conducted on mice were successful.
Even more exciting, Dentistry Today reports, is that Takahashi's previous research shows that humans have a third row of teeth in their mouths. Those teeth are available as buds, and Takahashi believes they can be activated.
The human trial for regrowing teeth is expected to last about 11 months, according to Popular Mechanics.
Originally, it will consist of 30 men between the ages of 30 and 64. A qualification is that they each must be missing a tooth, an article in New Atlas reports.
The article also states that if the trial is proven safe and effective, plans are to open the trial to patients between the ages of 2 to 7, who are missing at least four teeth.
Researchers hope to have the drug available by the year 2030, Popular Mechanics states.Missing A Tooth? Scientists Develop New Drug that Regrows Teeth first appeared on Men's Journal on Jul 20, 2025
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
The Japanese walking method is everywhere (and for good reason) – here's how to try it yourself
Walking trends and methods are something we are never short of on our social feeds, with many of us obsessed with tracking our daily step count. And now, another more international trend promises to boost your walking results tenfold: the Japanese Interval Walking Technique is the new method to improve cardio, lower blood pressure and even improve lower-body strength. What is the Japanese interval walking technique? Developed in Japan by researchers, the Japanese Interval Walking Technique, also known as 'Intermittent Walking' or 'Interval Walking Training' includes intervals of brisk and moderated paced walking in order to improve cardiovascular fitness, metabolism and health. The technique is outlined as follows: Walk at a brisk pace for 3 minutes: About 70-85% of your maximum heart rate (your max in beats per minute is 220 minus your age, just FYI). You should be able to speak, but you may find continuous talking a challenge. Walk at a more leisurely pace for 3 minutes and let your heart rate come down to 40-50% of your maximum heart rate. Repeat 5 times for a total of 30 minutes. What are the benefits of the Japanese walking technique? The Japanese Walking Technique is supported by the research of Dr Hiroshi Nose published in Mayo Clinic Proceedings. The researchers examined the effects of either interval walking, moderate intensity continuous walking or no walking. They found that the interval walking group saw significantly greater improvements in aerobic capacity, muscular strength and reductions in resting systolic blood pressure. The researchers concluded, "High-intensity interval walking may protect against age-associated increases in blood pressure and decreases in thigh muscle strength and peak aerobic capacity." What's my maximum heart rate? As you exercise, your heart rate will elevate. Your maximum heart rate is: 220 minus your age Training with a heart rate above this level can be dangerous. It's advised to work at a level that suits your fitness levels and heart health. The Japanese Interval Walking Technique outlines a target heart rate of 70-85% of your max heart rate. If you don't have a fitness tracker that measures heart rate, aim to push yourself to a level of exertion that is 7 or 8 out of 10, where talking feels challenging. Who is the Japanese walking technique for? This is one of those trends that is not only accessible, but backed by research, making it suitable for the majority of people looking to improve their health. It's low-impact and can be adjusted to suit a wide range of fitness levels, so it's therefore particularly beneficial for those who are older or have existing injuries that prevent them from taking part in high-impact exercise. That said, if you have existing conditions which may affect exercising at higher heart rates, consult your doctor before taking part in the technique. This article is not a substitute for medical advice. If you're at all worried about your health, especially if you have new symptoms, then book an appointment with your Might Also Like A ranking of the very best hair straighteners - according to our Beauty Editors Best party dresses to shop in the UK right now 11 products you'd be mad to miss from the Net A Porter beauty sale
Medscape
9 hours ago
- Medscape
Anesthetic Gas Emissions Show Global Regional Disparities
TOPLINE: An analysis of greenhouse gas emissions from volatile anesthetic agents across 41 countries showed that Western nations have achieved significant reductions, but Asian countries continue to increase their use of the agents. South Korea and Japan reported the highest global per capita emissions. METHODOLOGY: Researchers conducted a multicounty analysis to estimate greenhouse gas emissions from volatile anesthetics using sales data obtained from IQVIA MIDAS and national medicines agencies. They calculated kilograms of carbon dioxide (CO 2 ) equivalents per capita as an indicator of greenhouse gas emissions focusing on sales of desflurane, isoflurane, and sevoflurane in 41 countries, representing approximately 35% of the global population. ) equivalents per capita as an indicator of greenhouse gas emissions focusing on sales of desflurane, isoflurane, and sevoflurane in 41 countries, representing approximately 35% of the global population. The analysis compared emissions among 27 nations in the European Union with those among other Western countries like Australia, Canada, New Zealand, the UK, and the US. Emissions among Asian countries such as China, Hong Kong, Japan, Malaysia, South Korea, Singapore, Taiwan, and Thailand were also analyzed. Time trends and percentage changes in greenhouse gas emissions related to the procurement of volatile anesthetics from 2018 to 2023 were presented for all the groups. TAKEAWAY: Canada, New Zealand, and the UK showed a 65%-95% reduction in CO 2 equivalent emissions, achieving levels below 0.5 kg of CO 2 equivalents per inhabitant by 2023. Australia and the United States, despite reductions, still had higher levels of emissions. equivalent emissions, achieving levels below 0.5 kg of CO equivalents per inhabitant by 2023. Australia and the United States, despite reductions, still had higher levels of emissions. Asian countries saw substantial increases in emissions related to volatile anesthetics, with South Korea and Japan having approximately 2.5 kg of CO 2 equivalents per inhabitant in 2023 and China experiencing a 130% rise in emissions from 2018 to 2023. equivalents per inhabitant in 2023 and China experiencing a 130% rise in emissions from 2018 to 2023. Emissions also increased from 2018 to 2023 in some countries, including Malta, Serbia, the Czech Republic, and the Russian Federation. Trends in emissions varied across Europe; Northern countries like Finland, Norway, and the UK showed a reduction in emissions from 1-2 kg to less than 0.5 kg of CO 2 equivalents per inhabitant, whereas Denmark and Estonia maintained low levels of emissions. Italy, Portugal, and Spain saw minimal reductions. IN PRACTICE: 'The experience of nations that were receptive to awareness campaigns and phased out desflurane use show that reducing emissions below 0.5 kg of CO 2 e [equivalents] per inhabitant is attainable. This success should serve as a model for all the other countries, prompting them to implement educational initiatives for anaesthetists and adopt specific policies to mitigate emissions from inhalational anaesthetics,' the researchers reported. SOURCE: The study was led by Marta Caviglia, of the Centre for Research and Training in Disaster Medicine, Humanitarian Aid and Global Health, at the Università del Piemonte Orientale in Novara, Italy. It was published online on August 6, 2025, in Anaesthesia. LIMITATIONS: The study considered only greenhouse gas emissions from atmospheric release of volatile anesthetic agents, not accounting for emissions during production, packaging, transport, storage, and disposal phases. While data were available for 41 countries, there was clear overrepresentation of high-income nations, with incomplete or unavailable data from South America, Africa, and some Asian countries, including India. The analysis did not account for nitrous oxide emissions. DISCLOSURES: No external funding or competing interests were declared by the authors. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
a day ago
Officials are investigating the cause of a Pennsylvania steel plant explosion that killed 2
CLAIRTON, Pa. -- An explosion rocked a steel plant outside Pittsburgh, leaving two dead and 10 others injured, including a person who was rescued from the smoldering rubble after hours of being trapped. The explosion sent black smoke spiraling into the midday Monday sky in the Mon Valley, a region of the state synonymous with steel for more than a century. Allegheny County Emergency Services said a fire at the plant in Clairton started late Monday morning. Officials said they had not isolated the cause of the blast. The rumbling from the explosion, and several smaller blasts that followed, jolted the community about 15 miles (24 kilometers) southeast of Pittsburgh. Amy Sowers, who was sitting on her porch less than a mile from the plant, felt her house shake. 'I could see smoke from my driveway,' she said. 'We heard ambulances and fire trucks from every direction.' Sowers, 45, grew up in Clairton and has seen several incidents at the plant over the years. 'Lives were lost again,' Sowers said. 'How many more lives are going to have to be lost until something happens?' At a news conference, Scott Buckiso, U.S. Steel's chief manufacturing officer, did not give details about the damage or casualties, and said they were still trying to determine what happened. He said the company, now a subsidiary of Japan-based Nippon Steel Corp., is working with authorities. Allegheny Health Network said it treated seven patients from the plant and discharged five within a few hours. University of Pittsburgh Medical Center said it is treating three patients at UPMC Mercy, the region's only level one trauma and burn center. According to the company, the plant has approximately 1,400 workers. In a statement, the United Steelworkers, which represents many of the Clairton plant's workers, said it had representatives on the ground at the plant and would work to ensure there is a thorough investigation. David Masur, executive director of PennEnvironment, an environmental group that has sued U.S. Steel over pollution, said there needed to be 'a full, independent investigation into the causes of this latest catastrophe and a re-evaluation as to whether the Clairton plant is fit to keep operating.' U.S. Steel CEO David B. Burritt said the company would investigate. It's not the first explosion at the plant. A maintenance worker was killed in a blast in September 2009. In July 2010, another explosion injured 14 employees and six contractors. According to online OSHA records of workplace fatalities, the last death at the plant was in 2014, when a worker was burned and died after falling into a trench. After the 2010 explosion, the Occupational Safety and Health Administration fined U.S. Steel and a subcontractor $175,000 for safety violations. U.S. Steel appealed its citations and fines, which were later reduced under a settlement agreement. In February, a problem with a battery at the plant led to a 'buildup of combustible material' that ignited, causing an audible 'boom,' officials said. Two workers received first aid treatment but were not seriously injured. The plant, a massive industrial facility along the Monongahela River, is considered the largest coking operation in North America and is one of four major U.S. Steel plants in Pennsylvania. The plant converts coal to coke, a key component in the steelmaking process. To make coke, coal is baked in special ovens for hours at high temperatures to remove impurities that could otherwise weaken steel. The process creates what's known as coke gas — made up of a lethal mix of methane, carbon dioxide and carbon monoxide. The county health department initially told residents within 1 mile (1.6 kilometers) of the plant to remain indoors and close all windows and doors, but lifted the advisory later Monday. It said its monitors didn't detect levels of soot or sulfur dioxide above federal standards. U.S. Steel has been a symbol of industrialization since it was founded in 1901 by J.P. Morgan, Andrew Carnegie and others. It's been the icon of the American steel industry that once dominated the world market until Japan, then China, became preeminent steelmakers over the past 40 years. In June, U.S. Steel and Nippon Steel announced they had finalized a 'historic partnership,' a deal that gives the U.S. government a say in some matters and comes a year and a half after the Japanese company first proposed its nearly $15 billion buyout of the iconic American steelmaker. The pursuit by Nippon Steel for the Pittsburgh-based company was buffeted by national security concerns and presidential politics in a premier battleground state, dragging out the transaction for more than a year after U.S. Steel shareholders approved it. ___
